CRYSVITA® (burosumab-twza) is the only FDA-approved medicine for adults and children 6 months of age and older with X-linked hypophosphatemia (XLH). CRYSVITA works by targeting the underlying cause of this progressive and lifelong disease.
Why CRYSVITA
“Just the fact that I have been able to participate in life more has been a gift.”
– Karen, age 40, living with XLH
People of all ages open up about their lifelong journey with XLH and their experience with CRYSVITA.
With XLH, the body doesn’t retain enough phosphorus—a mineral that’s important for healthy bones. This can cause bones to weaken over time (a condition called osteomalacia). CRYSVITA can help the body reabsorb and retain a normal amount of phosphorus.
CRYSVITA has been studied in a total of 126 children with XLH and 148 adults with XLH.
Our dedicated team of specialists at UltraCare® Patient Services is available to help you gain access to CRYSVITA.
A completed Start Form is required for enrollment in UltraCare Patient Services. Talk to your healthcare team.
Learn about XLH and CRYSVITA from a clinical specialist and hear inspiring stories from people living with XLH and their caregivers.
